Drug intelligence / Profile preview

GC801

Development stage: Unknown
Lead developer: GeneCradle
Modality: Recombinant Proteins and Enzymes
Administration: Intravenous

Overview

GC801 is an investigational IgG-degrading enzyme (protease) developed by The Seventh Medical Center of Chinese PLA General Hospital. It is specifically designed to eliminate serum anti-adeno-associated virus serotype 9 (AAV9) antibodies in pediatric patients with Pompe disease. Pre-existing anti-AAV antibodies often preclude patients from receiving AAV-based gene therapies; GC801 functions by enzymatically cleaving these antibodies, thereby creating a window for the successful administration of AAV9-delivered therapeutic genes. It is currently being evaluated in Phase 1 clinical trials in China.

Beyond the preview

Go deeper on GC801.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GC801.

Explore the full profile